BRAF and melanoma: Immunotherapy (e.g., ipilimumab, nivolumab, pembrolizumab) and target therapy (e.g., vemurafenib/cobimetinib, dabrafenib/trametinib in case of BRAF mutation) have increased the progression-free and overall survival in melanoma patients [29,30].